2 results
Approved WMOCompleted
*To demonstrate comparability of the ORR in patients with previously untreated, advanced stage FL who receive GP2013-CVP combination treatment to patients who receive MabThera®-CVP treatment. ORR will be determined during the combination treatment…
Approved WMORecruiting
To assess the safety and biodistribution of 89Zr-pembrolizumab and its uptake in tumor and target irAE tissues